

User Interface Design and Evaluation

AOL243Q - 2018


What's it all about ?

You being able to:

- design and evaluate user interfaces
- understand the techniques used in the field
(think aloud, heuristic evaluation & more!)
- understand the science behind this!

Human-Computer Interaction

Human-Robot Interaction




**User-Centered Design
Requirements Engineering
Human Aspects of Computer Science
Quantitative Experimentation**

Interface design & Prototyping & Evaluation
Design Evaluation & Experiments, Analysis, Reporting

Course Credits

Attendance	10 %	10	10	10
Assignments / Exercises	n %	30	40	60
Project	n %	60	50	30

Attendance ?



Study at King's College London



Isabelle,
Management BSc

My experience at King's has been fantastic. The course is challenging, varied and studying in London provides plenty of opportunities to build skills for my future career.

Find the right course for you

Search courses





Frank Soboczenski

Computer Scientist

School of Population Health & Environmental Sciences
Medical Faculty
King's College London

Frank Soboczenski

Computer Scientist

School of Population?Health & Environmental Sciences
Medical?Faculty
King's College London

DFKI ERHÄLT ERSTEN NVIDIA DGX-2 SUPERCOMPUTER IN...

Einzigartige Infrastruktur für Deep Learning – Das Deutsche Forschungszentrum für Künstliche Intelligenz (DFKI) erhält als erste Institution in Europa...

[» ZUM ARTIKEL](#)



EVENTS & KEYNOTES



Artificial Intelligence – International Research and Applications: 1st Japanese-German-French

A large, colorful abstract network graph composed of numerous small nodes connected by thin lines, forming a complex web-like structure.


sps ipc drives




smart and digital automation
29th international exhibition
Nuremberg, Germany, 27–29 November 2018

Wednesday was a special day at DFKI Berlin: A cooperation contract between the Beijing AI Technology Center and the DFKI has been signed. Due to the special occasion, Mr. Yin Hejun, vice major of Beijing, Mr. Xu Quiang (Director-General of Beijing Municipal Commission of Economy and Information Technology) and Mr. Wang Gang (Beijing Municipal Commission of Economy and Information Technology) honoured our office with their visit. In this context, the AITC will move into new premises located at the headquarters of the DFKI Berlin. We are looking forward to a successful cooperation with our partner from Peking!





Reducing Number-Entry Errors in Healthcare



More on This Story

Baroness Thatcher 1925-2013



Baroness Thatcher dies


Reaction as former UK Prime Minister Margaret Thatcher dies following a strike, her spokesman says.



Your Score: 0


496.21

7 8 9
4 5 6
1 2 3
0 . Enter
Clear





Extreme Value Analysis



Block Maxima



RobotReviewer: Automating ev

Secure | https://robotreviewer-ux.vortexsystems/doc/#document/pyhKEGTdvbeXrlBPcw0Nv/sFFof9JzAiWfrvlAomFAq?annotation_type=bias_bot&ux_uuid=iGFlxT6wH2or... ☆ G S 1 6 X 0 :

RobotReviewer

CHEST

Original Research

ASTHMA

Efficacy and Safety of Fluticasone Furoate/Vilanterol Compared With Fluticasone Propionate/Salmeterol Combination in Adult and Adolescent Patients With Persistent Asthma

A Randomized Trial

Ashley Woodcock, MD; Eugene R. Bleecker, MD, FCCP; Jan Lötvall, PhD; Paul M. O'Byrne, MD, FCCP; Eric D. Bateman, MD; Hilary Medley, PGDip; Anna Ellsworth, BS; Loretta Jacques, PhD; and William W. Busse, MD

Background: The combination of fluticasone furoate (FF), a novel inhaled corticosteroid (ICS), and vilanterol (VI), a long-acting β_2 agonist, is under development as a once-daily treatment of asthma and COPD. The aim of this study was to compare the efficacy of FF/VI with fluticasone propionate (FP)/salmeterol (SAL) in patients with persistent asthma uncontrolled on a medium dose of ICS.

Methods: In a randomized, double-blind, double-dummy, parallel group study, 806 patients received FF/VI (100/25 μ g, n = 403) once daily in the evening delivered through ELLIPTA (GlaxoSmithKline) dry powder inhaler, or FP/SAL (250/50 μ g, n = 403) bid through DISKUS/ACCUHALER (GlaxoSmithKline). The primary efficacy measure was 0- to 24-h serial weighted mean (wm) FEV₁ after 24 weeks of treatment.

Results: Improvements from baseline in 0- to 24-h wmFEV₁ were observed with both FF/VI (341 mL) and FP/SAL (377 mL); the adjusted mean treatment difference was not statistically significant (-37 mL; 95% CI, -88 to 15 , $P = 0.162$). There were no differences between 0- to 4-h serial wmFEV₁, trough FEV₁, and asthma control and quality-of-life questionnaire scores. There was no difference in reported exacerbations between treatments. Both treatments were well tolerated, with no clinically relevant effect on urinary cortisol excretion or vital signs and no treatment-related serious adverse events.

Conclusions: The efficacy of once-daily FF/VI was similar to bid FP/SAL in improving lung function in patients with persistent asthma. No safety issues were identified.

Trial registry: ClinicalTrials.gov; No.: NCT01147848; URL: www.clinicaltrials.gov

CHEST 2013; 144(4):1222–1229

Abbreviations: AE = adverse event; AQLQ+12 = Asthma Quality of Life + 12 Questionnaire; EQ-5D = European Quality of Life-5 Dimensions; FF = fluticasone furoate; FP = fluticasone propionate; ICS = inhaled corticosteroid; LABA = long-acting β_2 agonist; SAE = serious adverse event; SAL = salmeterol; UC = urinary cortisol; VI = vilanterol.

Next

Risk of Bias

Random Sequence Generation

Overall risk of bias prediction: Low

The central randomization schedule was generated by the sponsor with a validated com...
The aim of this study was to compare the effi cacy of FF/VI with fl uticasone propionate ...
Patients were randomized by the Registration and Medication Ordering System.

Allocation Concealment

Overall risk of bias prediction: Low

The central randomization schedule was generated by the sponsor with a validated com...
Patients were randomized by the Registration and Medication Ordering System.
The aim of this study was to compare the effi cacy of FF/VI with fl uticasone propionate ...

Blinding Of Participants And Personnel

Overall risk of bias prediction: Low

Neither the patients nor the investigator knew which study medication the patient was r...
This phase 3, multicenter, randomized, double-blind, doubledummy , parallel group stud...
As a consequence of site audits conducted by the study sponsor GlaxoSmithKline, con...

Blinding Of Outcome Assessment

Overall risk of bias prediction: Low

The authors and study sponsor are satisfi ed that the exclusion of data derived from the...
See Table 1legend for expansion of other abbreviations., and performed the statistical a...
The central randomization schedule was generated by the sponsor with a validated com...

